Evidence map›Paper›PMID 38022076›Full record

ArticleCureus2023

Hepatic Involvement as the Sole Presentation of Systemic Amyloid Light Chain (AL) Amyloidosis: A Diagnostic Challenge.

Nadeer Kottavadakkeel, Arun Rajaram

Abstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nadeer KottavadakkeelGastroenterology, Pilgrim Hospital Boston, United Lincolnshire Hospital NHS Trust, Boston, GBR.
Arun RajaramOtolaryngology, Pilgrim Hospital Boston, United Lincolnshire Hospital NHS Trust, Boston, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary systemic amyloidosis is generally a systemic condition and only a few of systemic amyloidosis cases manifest with signs of single-organ involvement. The occurrence of symptoms and signs of hepatic involvement alone in primary systemic amyloidosis is rare, presenting a diagnostic challenge. In this case, a 55-year-old lady presented with nonspecific symptoms such as weight loss and loss of appetite. She was found to have mildly deranged liver function tests with a cholestatic pattern, and there were no apparent risk factors for liver disease. Clinical features of involvement in other organs were notably absent. After ruling out common causes of cholestatic liver disease, we considered the possibility of infiltrative liver disease and arranged for a liver biopsy, which revealed the diagnosis of amyloidosis. In summary, while hepatic deposition is a relatively common consequence of systemic amyloidosis, it is exceptionally rare for a patient to present with clinical features of liver involvement alone. This rarity presents a significant diagnostic challenge. Given the infrequency of this presentation, a diagnosis of amyloidosis should be considered only after diligently excluding other more common causes of hepatomegaly, whether associated with abnormal liver function tests or not.

Indexed as

al amyloidosisapple-green birefringencecongo red stainhepatic amyloidosishepatomegalyinfiltrative liver disease

Identifiers

PMID38022076
PMCPMC10656702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.